- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | PSYENCE BIOMEDICAL LTD. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 09.10. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 06.10. | PSYENCE BIOMEDICAL LTD. - F-1/A, Registration statement for certain foreign private issuers | 4 | SEC Filings | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 05.09. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 04.08. | Psyence Biomedical Ltd.: Corporate Update, August 2025 | 283 | GlobeNewswire (Europe) | NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe... ► Artikel lesen | |
| 01.08. | Pre-market Movers: Namib Minerals, 4D Molecular Therapeutics, CCC Intelligent Solutions, Enovix, Psyence Biomedical | 777 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.25 A.M. ET).In the Green Namib Minerals (NAMM) is up over 108% at $8.26.
4D... ► Artikel lesen | |
| 31.07. | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | 657 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
| 31.07. | Psyence Biomedical stock soars after partner achieves ibogaine breakthrough | 15 | Investing.com | ||
| 31.07. | Psyence Biomedical Ltd.: Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production | 225 | GlobeNewswire (Europe) | NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs - a leader in the production... ► Artikel lesen | |
| 23.07. | PSYENCE BIOMEDICAL LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.06. | Psyence Biomedical Ltd.: Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 | 390 | Newsfile | Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") - the world's... ► Artikel lesen | |
| 17.06. | Psyence BioMed regains Nasdaq compliance following reverse stock split | 1 | Seeking Alpha | ||
| 17.06. | Psyence Biomedical regains Nasdaq compliance after reverse split | 4 | Investing.com | ||
| 17.06. | Psyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements | 295 | Newsfile | New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq... ► Artikel lesen | |
| 11.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi | 2 | Investing.com | ||
| 27.05. | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | 395 | Newsfile | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 3,130 | +2,79 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 15,260 | +1,67 % | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| SILEXION THERAPEUTICS | 3,715 | +4,94 % | Silexion Therapeutics Corp: Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer | New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence... ► Artikel lesen | |
| MINK THERAPEUTICS | 11,300 | +1,80 % | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 189,99 | +16,77 % | Praxis Precision Medicines prices $525M public offering | ||
| QIAGEN | 41,345 | +0,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| RANI THERAPEUTICS | 1,640 | +248,20 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| NUVALENT | 92,52 | +2,32 % | Stifel initiates coverage on Nuvalent stock with Buy rating | ||
| RECURSION PHARMACEUTICALS | 5,860 | -7,86 % | Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event | ||
| KYMERA THERAPEUTICS | 59,83 | -1,11 % | The Analyst Verdict: Kymera Therapeutics In The Eyes Of 6 Experts | ||
| IMMUNOVANT | 17,510 | +0,57 % | Truist Securities initiates Immunovant stock with Hold rating, $16 target | ||
| COGENT BIOSCIENCES | 16,390 | +0,18 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TREVI THERAPEUTICS | 10,360 | -2,45 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,030 | -5,18 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger | ||
| ARTIVA BIOTHERAPEUTICS | 6,020 | +118,12 % | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate... ► Artikel lesen |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.